Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, Agustí À, Tal-Singer R, Han MK, Janssens W, Hanania NA, Nair P, Bremner P, Porpodis K, Shibata Y, Korn S, Yang T, Gordon O, Saenz R, Ng J, Cheung DS, Devine J, Grimbaldeston MA, Zhang W, Yang X, Mohan D, Vogelmeier CF, Brightling CE, ALIENTO and ARNASA investigators

Open source

DOI: 10.1016/s0140-6736(26)00637-9
Published: 2026 May 23
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00637-9,
  title = {Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.},
  author = {Papi A and Greening NJ and Bhatt SP and Roche N and Celli B and Wedzicha JA and Agustí À and Tal-Singer R and Han MK and Janssens W and Hanania NA and Nair P and Bremner P and Porpodis K and Shibata Y and Korn S and Yang T and Gordon O and Saenz R and Ng J and Cheung DS and Devine J and Grimbaldeston MA and Zhang W and Yang X and Mohan D and Vogelmeier CF and Brightling CE and ALIENTO and ARNASA investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00637-9},
  url = {https://doi.org/10.1016/s0140-6736(26)00637-9}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.
AU  - Papi A
AU  - Greening NJ
AU  - Bhatt SP
AU  - Roche N
AU  - Celli B
AU  - Wedzicha JA
AU  - Agustí À
AU  - Tal-Singer R
AU  - Han MK
AU  - Janssens W
AU  - Hanania NA
AU  - Nair P
AU  - Bremner P
AU  - Porpodis K
AU  - Shibata Y
AU  - Korn S
AU  - Yang T
AU  - Gordon O
AU  - Saenz R
AU  - Ng J
AU  - Cheung DS
AU  - Devine J
AU  - Grimbaldeston MA
AU  - Zhang W
AU  - Yang X
AU  - Mohan D
AU  - Vogelmeier CF
AU  - Brightling CE
AU  - ALIENTO and ARNASA investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00637-9
UR  - https://doi.org/10.1016/s0140-6736(26)00637-9
ER  -

APA

A, P., NJ, G., SP, B., N, R., B, C., JA, W., À, A., R, T., MK, H., W, J., NA, H., P, N., P, B., K, P., Y, S., S, K., T, Y., O, G., R, S., J, N., DS, C., J, D., MA, G., W, Z., X, Y., D, M., CF, V., CE, B., & investigators, A. A. A. (2026). Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00637-9

Source records

pubmed · retrieved 2026-09-26T07:56:05.928Z